Morrisville, N.C., September 13, 2021 — Health Decisions, A Division of Premier Research, will support the Women’s Health Innovation Summit as an Associate Partner for the third year.
On Tuesday, September 14 from 12:10 p.m. to 12: 45 p.m. EDT, Health Decisions, an organization that provides clinical research specific to women’s health, will present a case study entitled “Optimizing Study Enrollment During the Covid-19 Pandemic” examining best practices for study design, site selection, patient engagement, and building collaborative sponsor-CRO partnerships in the context of women’s health trials. Additionally, it will include a review of the recruitment process, which enrolled patients nearly twice as fast as anticipated, despite launching just as the COVID-19 pandemic began to shut down most of the U.S.
- Dr. Mary Gunn, Chief Operating Officer, Health Decisions
- Sabrina Johnson President & CEO, Dare Biosciences
- Jessica Hatheway, Clinical Operations, Health Decisions
Meet the speakers after their presentation for networking drinks hosted by Health Decisions from 6-7 p.m. EDT.
The Summit will be held Tuesday, September 14 and Wednesday, September 15, 2021, at The Westin Copley Place in Boston, Massachusetts. In addition, a “Virtual Day” is also scheduled for Tuesday, September 28, 2021, with live discussions and on-demand content.
The Summit is considered the sector’s leading platform committed to strengthening the women’s health network, tackling unmet needs, and championing innovative approaches and solutions for the critically underserved women’s health industry. It focuses on female-only health challenges, female-prevalent diseases, and conditions that affect or present differently in women.
Attendees can find a link to registration here: https://www.kisacoresearch.com/events/womens-health-innovation-summit-2021
Each year, the Summit is supported and attended by a network of pharmaceutical companies, biotechnology firms, medical device companies, startups, femtech, insurers, CROs, investors, researchers, HCPs, and advocacy groups. Participants are committed to driving innovation at the convergence of healthcare and technology.
About Health Decisions
Health Decisions, A Division of Premier Research, is a full-service contract research organization (CRO) offering therapeutic, operational, and regulatory excellence for the clinical development of drugs, medical devices, and combination drug/devices in indications that impact women profoundly and disproportionately. Based on years of experience and aided by a site network of more than 500 high-performing women’s health sites, Health Decisions delivers clinical studies tailored to meet sponsor, patient, and regulatory needs. More than 90 percent of the Health Decisions’ staff specialize in women’s health research, allowing for hand-selected study teams uniquely suited to address the challenges of developing assets in areas including reproductive and sexual health, menopause, pain management, osteoporosis, osteoarthritis, and gynecologic oncology. Additionally, Health Decisions conducts diagnostic and medical device studies in all therapeutic indications, including women’s health, oncology, and infectious disease. For more information, visit www.healthdec.com.
Media Contact: Jennifer Peters, Marketing Specialist, email@example.com